Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF is a therapeutic target in aggressive thyroid carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Mar 2006

Salvatore Giuliana, De Falco Valentina, Salerno Paolo, Nappi Tito Claudio, Pepe Stefano, Troncone Giancarlo, Carlomagno Francesca, Melillo Rosa Marina, Wilhelm Scott M, Santoro Massimo

Abstract excerpt

PURPOSE: Oncogenic conversion of BRAF occurs in approximately 44% of papillary thyroid carcinomas and 24% of anaplastic thyroid carcinomas. In papillary thyroid carcinomas, this mutation is associated with an unfavorable clinicopathologic outcome. Our aim was to exploit BRAF as a potential therapeutic target for thyroid carcinoma. EXPERIMENTAL DESIGN: We used RNA interference to evaluate the effect of BRAF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzenesulfonates
Share to Carcinoma, Papillary

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Niacinamide

Share to Phenylurea Compounds

Share to Pyridines

Share to Sorafenib

Share to Thyroid Gland

Share to Transplantation, Heterologous

Source

Identifiers

PMID: 16533790
DOI: 10.1158/1078-0432.CCR-05-2378

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF is a therapeutic target in aggressive thyroid carcinoma.PMID 16533790Read ↗

Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.Semantic proximity Read ↗

Targeting BRAF in thyroid cancer.Semantic proximity Read ↗

BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future PerspectivesSemantic proximity Read ↗

Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.Semantic proximity Read ↗

Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E).Semantic proximity Read ↗

BRAF V600E inhibition in anaplastic thyroid cancer.Semantic proximity Read ↗

Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.Semantic proximity Read ↗

Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancer.Semantic proximity Read ↗

Role of BRAF in thyroid oncogenesis.Semantic proximity Read ↗

BRAF and MEK inhibition beyond dabrafenib-trametinib in advanced thyroid cancer: a real-world case series.Semantic proximity Read ↗

Aberrant BRAF splicing as an alternative mechanism for oncogenic B‐Raf activation in thyroid carcinomaSemantic proximity Read ↗

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.